FDA panel votes in favor of approving GSK’s multiple myeloma drug
FDA panel votes in favor of approving GSK’s multiple myeloma drug
An independent panel to the U.S. Food and Drug Administration on Tuesday voted in favor of approving GlaxoSmithKline’s experimental treatment for a common form of blood cancer, saying the benefits of the treatment outweigh the risks. Read More